Skip to main content

Table 4 Standard and modified thromboelastography with and without fresh frozen plasma administration (pooled data)

From: Molecular adsorbent recirculating system and hemostasis in patients at high risk of bleeding: an observational study

  TP1 TP2 TP3 p
Patients with FFP administration     
   Reaction time (mm) 19.4 (13.8–25.6) 20 (15.9–23.9) 17.4 (15.1–23) 0.46
   Coagulation time (mm) 16 (9.1–37.8) 25.5 (10.2–45.7) 25.1 (13–33.9) 0.02
   Maximal amplitude (mm) 34.2 (23.2–42.2) 29 (22.5–43) 29.7 (20.5–40.5) 0.015
   Angle alpha (degree) 30.2 (17–51.2) 34.2 (18.5–45.7) 21 (17.5–37) 0.06
   Clot lysis 100 (100-100) 100 (100-100) 100 (100-100) 0.84
   Coagulation index (percent) -2.2 (-14.4–2.5) -5 (-11.5–1.9) -4.7 (-8.6–1.1) 0.9
   RHEP (mm) 1 (-0.7–2.2) 3 (-0.1–6.8) 0.7 (-0.6–4.1) 0.64
   MAPLT (mm) 20 (12–30.3) 21.5 (15–31) 24 (13.8–32.2) 0.22
Patients without FFP administration     
   Reaction time (mm) 15.9 (13–19.4) 16.8 (13–19.3) 16.4 (10.9–20.5) 0.71
   Coagulation time (mm) 11.3 (7–19.7) 9.4 (6.3–21) 14.2 (5–32) 0.6
   Maximal amplitude (mm) 40 (32–52) 37.5 (28.3–52.6) 36.5 (24.8–53.3) 0.006
   Angle alpha (degree) 35.5 (28.5–51) 47.5 (30–57) 35.5 (21.2–57.7) 0.028
   Clot lysis (percent) 100 (98.6–100) 100 (98.6–100) 100 (97.8–100) 0.77
   Coagulation index 0.38 (-3.4–4.2) -0.1 (-2.3–3.8) 0.3 (-7.7–4.8) 0.73
   RHEP (mm) 0.7 (-0.4–2.8) 2.9 (0.3–4.7) 1.9 (0.7–4) 0.03
   MAPLT (mm) 24.4 (12.5–31.2) 20 (8.5–27.5) 13.5 (6.2–27.5) 0.95
  1. MAPLT, difference between standard and abximimab-fab-modified maximal amplitude (MA) reflecting solely the platelet function. RHEP, difference between standard and heparinase modified reaction time (R) reflecting the effects of endo/exogenous heparinoids on plasmatic coagulation. FFP, fresh frozen plasma; TP, time point